SCHEMBL6485691

SCHEMBL6485691

CC(C)(C)[Si](C)(C)Oc1ccc([C@H]2CC[C@@H](NS(C)(=O)=O)CC2)c(O[Si](C)(C)C(C)(C)C)c1

nearest known ligand 0.40

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
PGR P06401 1/20 0.37
HTR2A P28223 4/20 0.37
DRD3 P35462 4/20 0.37
DRD2 P14416 3/20 0.37
CA12 O43570 4/20 0.36
CA1 P00915 4/20 0.36
CA9 Q16790 4/20 0.36
PREP P48147 2/20 0.35
CYP4F2 P78329 1/20 0.35
CYP4A11 Q02928 1/20 0.35
CNR2 P34972 2/20 0.33
L3MBTL1 Q9Y468 1/20 0.33
NPY5R Q15761 1/20 0.33
BRD4 O60885 1/20 0.32
BRD2 P25440 1/20 0.32
BRD3 Q15059 1/20 0.32
MAPT P10636 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6486732 1.00 PGR (0.37) PGRHTR2ADRD3DRD2CA12
SCHEMBL6433894 1.00 PGR (0.37) PGRHTR2ADRD3DRD2CA12
SCHEMBL5360944 0.87 POLB (0.40) HTR2ADRD3DRD2CNR2
SCHEMBL5360942 0.87 POLB (0.40) HTR2ADRD3DRD2CNR2
SCHEMBL5363019 0.86 HTR1A (0.42) HTR2ADRD3DRD2BRD4BRD2
SCHEMBL5356423 0.86 HTR1A (0.42) HTR2ADRD3DRD2BRD4BRD2
SCHEMBL5356429 0.86 HTR1A (0.42) HTR2ADRD3DRD2BRD4BRD2
SCHEMBL5360089 0.85 L3MBTL1 (0.34) HTR2ADRD2CA12CA1CA9
SCHEMBL5446985 0.85 POLB (0.42) HTR2ADRD3DRD2L3MBTL1
SCHEMBL5363070 0.85 ALDH1A1 (0.45) HTR2ADRD3DRD2L3MBTL1BRD4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6933319-B2 Resorcinol derivatives PFIZER INC. (US) 2005-08-23 US disclosed
US-6828460-B2 Containing at least one ester, oxime, sulfonamide, hydroxyamino or alkyoxyamino functionality; skin lightening agents; tyrosinase inhibitors PFIZER INC. 2004-12-07 US disclosed
US-20040209949-A1 Resorcinol derivatives BROWNING ANDREW FRANCIS (SE) 2004-10-21 US disclosed
US-20020161041-A1 Resorcinol derivatives PFIZER INC. 2002-10-31 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040209949-A1 Resorcinol derivatives NQO1, LRAT, ALDH1A2 PGR 721/4885HTR2A 2770/4885DRD3 434/4885
US-20020161041-A1 Resorcinol derivatives NQO1, LRAT, ALDH1A2 PGR 721/4885HTR2A 2770/4885DRD3 434/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.